Short Interest in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Declines By 32.9%

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the recipient of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 180,100 shares, a decrease of 32.9% from the February 28th total of 268,500 shares. Currently, 6.2% of the company’s stock are short sold. Based on an average daily volume of 630,700 shares, the short-interest ratio is currently 0.3 days.

CNS Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ:CNSP traded down $0.02 on Friday, reaching $1.30. 161,488 shares of the company’s stock were exchanged, compared to its average volume of 276,800. The business’s 50-day moving average is $3.86 and its two-hundred day moving average is $5.32. CNS Pharmaceuticals has a fifty-two week low of $1.21 and a fifty-two week high of $965.00. The firm has a market capitalization of $3.83 million, a price-to-earnings ratio of -0.02 and a beta of 2.65.

Institutional Investors Weigh In On CNS Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of CNSP. Wealthfront Advisers LLC acquired a new position in CNS Pharmaceuticals in the fourth quarter valued at approximately $26,000. Integrated Wealth Concepts LLC acquired a new position in CNS Pharmaceuticals during the 4th quarter valued at approximately $30,000. Connective Capital Management LLC acquired a new position in CNS Pharmaceuticals during the 4th quarter valued at approximately $34,000. XTX Topco Ltd bought a new position in CNS Pharmaceuticals during the 4th quarter worth $36,000. Finally, Citadel Advisors LLC acquired a new stake in CNS Pharmaceuticals in the fourth quarter worth $39,000. Institutional investors and hedge funds own 14.02% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on CNSP. Alliance Global Partners raised shares of CNS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 24th. Maxim Group reissued a “hold” rating on shares of CNS Pharmaceuticals in a report on Tuesday, March 25th.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.